Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
Biohaven Ltd. (BHVN) Stock Price & Analysis
289 Followers
BHVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.19 - $62.21
Previous Close$39.32
Volume872.87K
Average Volume (3M)1.40M
Market Cap
$3.47B
Enterprise Value$3.26B
Total Cash (Recent Filing)$240.60M
Total Debt (Recent Filing)$28.29M
Price to Earnings (P/E)-5.8
Beta2.46
Next Earnings
Jul 29, 2024EPS Estimate
-$1.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.84
Shares Outstanding88,291,909
10 Day Avg. Volume1,220,746
30 Day Avg. Volume1,404,470
Standard Deviation0.42
R-Squared0.23
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)8.08
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-13.61
Forecast
1Y Price Target
$58.88Price Target Upside49.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Biohaven Ltd. News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPreliminary safety and efficacy results from the phase 1 study of BHV-1300 are promising, showing no serious adverse events and potential for dose- and time-dependent IgG lowering.
Drug Development ProgressBiohaven's BHV-1300 program is rapidly evolving from an academic concept to a key driver of the company's valuation, reflecting its potential as a transformative treatment.
Upcoming EventsThe upcoming R&D day is expected to provide investors with a more comprehensive view of BHV-1300's safety and efficacy profile, potentially boosting confidence in the drug's future.
Bears Say
Drug Development ConcernsConcerns about the high dosage required for BHV-1300 raise questions about potential toxicity, making safety readouts a critical factor in future assessments.
Earnings ExpectationGAAP EPS of ($1.81), moderately below analyst estimates.
Financial PerformanceNon-GAAP loss per share increased and R&D expenses surged 120.0% YoY.
---
Ownership Overview
12.89% Insiders
18.59% Mutual Funds
46.19% Other Institutional Investors
22.33% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $14.19 and its highest was $62.21 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Currently, no data Available
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Jul 29, 2024 which is in 69 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on May 09, 2024. The company reported -$2.2 earnings per share for the quarter, missing the consensus estimate of -$1.549 by -$0.651.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -$1.78.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 88,291,910 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$2.2 in its last earnings report, missing expectations of -$1.549. Following the earnings report the stock price went down -13.709%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Among the largest hedge funds holding Biohaven Ltd.’s share is Perceptive Advisors LLC. It holds Biohaven Ltd.’s shares valued at 94M.
---
Biohaven Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.88 (49.75% Upside)
$58.88 (49.75% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 524.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $17.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.8%
Last 30 Days ▲ 31.4%
Last 30 Days ▲ 31.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
178.86%
12-Months-Change
Fundamentals
Return on Equity
-133.69%
Trailing 12-Months
Asset Growth
-32.33%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
---
BHVN Stock 12 Month Forecast
Average Price Target
$58.88
▲(49.75% Upside)
Technical Analysis
Best Analysts Covering BHVN
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+84.68%
reiterated a buy rating 10 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +84.68% per trade.
---